| Autor: |
Nash SD; Trachoma Control Program, The Carter Center, Atlanta, Georgia., Chernet A; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Astale T; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Sata E; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Zerihun M; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Nute AW; Trachoma Control Program, The Carter Center, Atlanta, Georgia., Jensen KA; Trachoma Control Program, The Carter Center, Atlanta, Georgia., Gessese D; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Ayele Z; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Melak B; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Haile M; Research and Technology Transfer Directorate, Amhara Public Health Institute, Bahir Dar, Ethiopia., Zeru T; Research and Technology Transfer Directorate, Amhara Public Health Institute, Bahir Dar, Ethiopia., Tadesse Z; Trachoma Control Program, The Carter Center, Addis Ababa, Ethiopia., Kelly Callahan E; Trachoma Control Program, The Carter Center, Atlanta, Georgia. |
| Abstrakt: |
Infants ages < 6 months do not receive azithromycin as part of trachoma control and thus may serve as an infection reservoir in persistently endemic districts. The aim of this study was to determine the population-based Chlamydia trachomatis infection prevalence and infectious load among infants ages 1-12 months in persistently trachoma endemic districts in Amhara, Ethiopia. Across six districts, 475 infants were enumerated, and of these 464 (97.7%) were swabbed for infection testing. The C. trachomatis infection prevalence in the study area among infants was 0.2% (95% CI: 0.0-1.5). Among children ages 0-5 years positive for C. trachomatis, the median load was 31 elementary bodies (EB) (Inter quartile range: 7-244 EB), and the infection-positive infant had a load of 7,755 EB. While it is worth reconsidering azithromycin treatment recommendations for the potential mortality benefits, these results do not support lowering the treatment age for trachoma control. |
